Life Sciences Group,Inc
Life Science Pharmaceuticals (LSP) is a biotech developer of therapeutics focused on oncology, diabetes and other serious diseases. The company advances a portfolio of preclinical and clinical-stage product candidates, with emphasis on monoclonal antibodies and antibody-drug conjugates, and maintains licensing and collaborative relationships with academic institutions and international pharmaceutical partners.
Industries
Nr. of Employees
small (1-50)
Life Sciences Group,Inc
Boca Raton, Florida, United States, North America
Products
EGFR-targeted monoclonal antibody programs
Monoclonal antibody candidates directed to a unique epitope on EGFR; programs have been advanced into clinical testing and out-licensed to pharmaceutical partners for further development.
EGFR-targeted antibody-drug conjugate (ADC) programs
ADC candidates combining EGFR-targeted antibodies with cytotoxic payloads developed for glioblastoma and other oncology indications; programs have been subject to regulatory designations and industry partnerships.
ABT-806
A humanized monoclonal antibody that selectively targets the epidermal growth factor receptor (EGFR), currently in Phase 1 clinical trial for the treatment of advanced solid tumors expressing EGFR.
Monoclonal antibody 806 (mAb806)
Monoclonal antibody 806 targets a proprietary epitope on EGFR, binding to cancer cells but not normal tissue cells. It offers tumor-specific targeting and has been shown to reduce tumor growth in preclinical studies. It is licensed to Life Science Pharmaceuticals and further developed by Abbott Biotechnology.
LSP monoclonal antibody (806)
A monoclonal antibody targeting a unique epitope of the EGFr, developed by Life Science Pharmaceuticals and licensed to AbbVie for further development.
ABT-414/806
A monoclonal antibody (806) targeting a unique epitope of the EGFr, developed by Life Science Pharmaceuticals and licensed to AbbVie for further development.
EGFR-targeted monoclonal antibody programs
Monoclonal antibody candidates directed to a unique epitope on EGFR; programs have been advanced into clinical testing and out-licensed to pharmaceutical partners for further development.
EGFR-targeted antibody-drug conjugate (ADC) programs
ADC candidates combining EGFR-targeted antibodies with cytotoxic payloads developed for glioblastoma and other oncology indications; programs have been subject to regulatory designations and industry partnerships.
ABT-806
A humanized monoclonal antibody that selectively targets the epidermal growth factor receptor (EGFR), currently in Phase 1 clinical trial for the treatment of advanced solid tumors expressing EGFR.
Monoclonal antibody 806 (mAb806)
Monoclonal antibody 806 targets a proprietary epitope on EGFR, binding to cancer cells but not normal tissue cells. It offers tumor-specific targeting and has been shown to reduce tumor growth in preclinical studies. It is licensed to Life Science Pharmaceuticals and further developed by Abbott Biotechnology.
LSP monoclonal antibody (806)
A monoclonal antibody targeting a unique epitope of the EGFr, developed by Life Science Pharmaceuticals and licensed to AbbVie for further development.
ABT-414/806
A monoclonal antibody (806) targeting a unique epitope of the EGFr, developed by Life Science Pharmaceuticals and licensed to AbbVie for further development.
Services
Structuring and executing licensing agreements and collaborative arrangements with academic institutions and pharmaceutical companies.
Structuring and executing licensing agreements and collaborative arrangements with academic institutions and pharmaceutical companies.
Expertise Areas
- Oncology therapeutics
- Monoclonal antibody development
- Antibody-drug conjugates
- Preclinical and early-stage clinical development
Key Technologies
- Monoclonal antibodies
- Antibody-drug conjugates (ADCs)
- Epitope-targeted therapeutics
- Early-phase clinical trial development
News & Updates
Announcement of initiation of a Phase 1 clinical trial for an EGFR-targeted monoclonal antibody.
Announcement of a license/collaboration agreement to develop an EGFR-targeted antibody program with a pharmaceutical partner.
A licensee of the company's program received EMA and FDA orphan drug designation for an investigational EGFR-targeted antibody-drug conjugate in glioblastoma.
Announcement of initiation of a Phase 1 clinical trial for an EGFR-targeted monoclonal antibody.
Announcement of a license/collaboration agreement to develop an EGFR-targeted antibody program with a pharmaceutical partner.
A licensee of the company's program received EMA and FDA orphan drug designation for an investigational EGFR-targeted antibody-drug conjugate in glioblastoma.